	US 12,070,450 B2
	Treatment of migraine
Joel M. Trugman, Hoboken, NJ (US); Ramesh Boinpally, Princeton, NJ (US); Abhijeet Jakate, Edison, NJ (US); and Michelle Finnegan, Madison, NJ (US)
Assigned to Allergan Pharmaceuticals International Limited, Dublin (IE)
Filed by Allergan Pharmaceuticals International Limited, Dublin (IE)
Filed on Nov. 29, 2023, as Appl. No. 18/523,481.
Application 18/523,481 is a continuation of application No. 18/210,719, filed on Jun. 16, 2023, granted, now 11,857,542.
Application 18/210,719 is a continuation of application No. 17/559,177, filed on Dec. 22, 2021, granted, now 11,717,515.
Claims priority of provisional application 63/129,379, filed on Dec. 22, 2020.
Prior Publication US 2024/0100029 A1, Mar. 28, 2024
Int. Cl. A61K 31/4375 (2006.01); A61K 31/4545 (2006.01); A61P 25/06 (2006.01)

CPC A61K 31/4375 (2013.01) [A61K 31/4545 (2013.01); A61P 25/06 (2018.01)]

4 Claims

1. A method for the acute treatment of migraine with or without aura in a patient undergoing treatment with a weak or moderate CYP3A4 inducer, the method comprising orally administering 100 mg ubrogepant to the patient, wherein the patient's migraine is safely and effectively treated.